Updates in Medicine | 🔬 REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio 👥 Phase 3a RCT in 1206 adults with T2D (BMI ≥27, HbA1c 7–10%) 💉 US$ 24.45 Min. order: 1 piece ★★★★★ 4.0 (272 reviews) Sold : Login>>
In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results US$ 26.31 Min. order: 1 piece ★★★★★ 4.2 (191 reviews) Sold : Login>>
GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction US$ 27.50 Min. order: 1 piece ★★★★★ 4.5 (36 reviews) Sold : Login>>
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity US$ 24.30 Min. order: 1 piece ★★★★★ 4.8 (16 reviews) Sold : Login>>
Good looking results for Novo Nordisk's combo of GLP1ra semaglutide (known as #ozempic for #diabetes & #wegovy for obesity) + Cagrilintide (amylin agonist) to achieve #weightloss in obesity and obesity with type US$ 24.11 Min. order: 1 piece ★★★★★ 4.1 (67 reviews) Sold : Login>>